CATALYSTYahoo • 1d ago
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
Why HALO Stock advanced +0.88% Today — RQD Quant Desk Flash
$131.18 +0.88% NASDAQ • Public Delayed / 60s Snapshot
Halozyme Therapeutics Inc. (HALO) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C+ • HOLD / WATCH
Cap $14.89B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw C+ · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE+4% Base Target
WHALE OPTIONS TUG-OF-WAR:60% Call Buyers ($2.7M)
40% PutsMax Pain: $129.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HALO Stock advanced +0.88% Today — RQD Quant Desk Flash
Halozyme Therapeutics Inc. (HALO) advanced +0.88% to $131.18 as options desks priced 60% call premium vs. 40% put protection around the $129 max-pain magnet. Solid 84% profit margin (18% return on capital), mixed timing at 47x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 96% of its 52-week range ($61.23 – $134) with RSI-14 at 78.7 (OVERBOUGHT (>70)).
- ▸Whale Options Positioning: $2.7M in bullish call flow vs. $1.8M in put flow (Put/Call 0.67x, implied earnings swing ±6.5%).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 83.6% gross margin and $644.6M annual free cash flow.
Live HALO Headlines & Catalysts
CATALYSTYahoo • 2d ago
Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $66.28 as of Oc
CATALYSTYahoo • 2d ago
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthHalozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RISK WATCHYahoo • 3d ago
What Did Halozyme Stock Investors Miss Before The Run?For questions about this article or underlying research, email help@trefis.com.
CATALYSTYahoo • 4d ago
Strong Royalties and New Launches Accelerate Halozyme Therapeutics’ (HALO) Growth MomentumRenaissance Investment Management, an investment management company, released its Q3 2026 investor letter for “Large Cap Growth Strategy.” The letter can be downloaded here. Stocks showed modest gains in Q3, with the S&P
RISK WATCHYahoo • 5d ago
TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataTango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
MARKET WIREYahoo • 5d ago
Incyte & Genmab Collaborate to Develop a New Colorectal Cancer TherapyINCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.
RISK WATCHYahoo • 5d ago
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallDr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
MARKET WIREYahoo • 8d ago
How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New HighsHalozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots
CATALYSTYahoo • 8d ago
BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.Oncology-focused biotech firm BeOne Medicines explores buy zone, boosted by strong demand and stellar earnings growth.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live HALO Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
HALO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +105.64%▲ RESISTANCE BREAKOUT
2026-10-30O $132.7H $134.0L $130.3C $130.9VOL 1.40M
RES: $130.0SUP: $95.62SMA50: $113.7SMA200: $83.37
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HALO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
34.7%/yr Implied 5Y Growth
vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HALO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HALO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HALO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
HALO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HALO stock moving today?
Why HALO Stock advanced +0.88% Today — RQD Quant Desk Flash. Solid 84% profit margin (18% return on capital), mixed timing at 47x P/E—hold if owned, no rush to chase.